Charles River (CRL) Q1 Earnings & Revenues Beat, Fall Y/Y
Yahoo Finance · 4 days ago
Open | 230.26 |
High | 230.90 |
Low | 223.78 |
Mkt Cap | 11.75B |
P/E (TTM) | 26.81 |
Div & Yield | N/A & N/A |
Prev. Close | 230.09 |
52 Wk. Low | 161.65 |
52 Wk. High | 275.00 |
Related stocks
Major US biomedical company
Charles River Laboratories International, Inc., is an American pharmaceutical company specializing in a variety of preclinical and clinical laboratory, gene therapy and cell therapy services for the Pharmaceutical, Medical device and Biotechnology industries. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 1.01B | 1.70% ▼ |
Net Income | 72.96M | 29.30% ▼ |
Diluted EPS | 2.27 | 35.30% ▼ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $2.62 | - |
Q1 2024 | $2.07 | $2.27 |
Q4 2023 | $2.40 | $2.46 |
S&P FuturesES=F | 5,250.25+4.00 (+0.08%) |
Dow FuturesYM=F | 39,640.00-2.00 (-0.01%) |
Nasdaq FuturesNQ=F | 18,285.50+30.50 (+0.17%) |
Bitcoin USDBTC-USD | 60,918.54-0.23% |
81.150+4.11% | |
Novavax, Inc.NVAX | 8.88+98.66% |